News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    

Clinical - Phase I
Cellular Biomedicine Group (CBMG) Announces Positive Phase I Results From CAR-T CD30 Immuno-Oncology Clinical Development Program 5/22/2015
IRB Approves Additional Enrollment In Cellceutix (CTIX)'s Clinical Trial Of New Cancer Drug Candidate For Solid Tumors 5/22/2015
Stock Soars as bluebird bio (BLUE) Gives Sneak Peek at Promising Sickle Cell Data 5/21/2015
Johnson & Johnson (JNJ) Announced 10 New Approval Applications with $1 Billion Revenue Potential Each 5/21/2015
e-Therapeutics plc Release: Progress In ETS2101 Phase Ib Study 5/21/2015
Isarna Therapeutics Announces Orphan Drug Designation In The European Union For ISTH0036 To Treat Advanced-Stage Glaucoma 5/21/2015
EMD Serono, Inc. Release: Rebif (interferon beta-1a) Data At CMSC Annual Meeting Highlights Clinical And MRI Predictors For Long Term Outcomes 5/21/2015
ContraFect (CFRXU) Announces First Healthy Volunteer Dosed With CF-301 5/21/2015
Calithera Biosciences, Inc. (CALA) Reports Initial Phase I Data For CB-839 In Patients With Acute Leukemias 5/21/2015
Kite Pharma (KITE) Announces That The First Patient In Its Phase I/II Clinical Trial Has Been Treated With KTE-C19, Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy, For Refractory Aggressive Non-Hodgkin's Lymphoma (NHL) 5/21/2015
RestorGenex Announces Data On The Effect Of RES-529 In Pulmonary Fibrosis Models 5/21/2015
Prothena (PRTA) Announces Presentation Of Clinical Data From The Ongoing Phase I/II NEOD001 Study And Systemic Amyloidosis Patient Survey Results At 20th Congress Of The European Hematology Association 5/21/2015
bluebird bio (BLUE) To Present Lentiglobin Clinical Data At 20th Congress Of European Hematology Association 5/21/2015
Oncolytics Biotech Inc. (ONC.TO) Announces Phase 1 Study In Pediatric Patients With Brain Tumors 5/19/2015
GlycoMimetics, Inc. (GLYC) Initiates Phase I/II Clinical Trial Of GMI-1271 As Potential Treatment For Acute Myeloid Leukemia In Combination With Chemotherapy 5/19/2015
GlycoMimetics, Inc. (GLYC) Initiates Phase I/II Clinical Trial Of GMI-1271 As Potential Treatment For Acute Myeloid Leukemia In Combination With Chemotherapy 5/19/2015
DURECT Corporation (DRRX) Announces Positive Results From DUR-928 Multi-Dose Phase 1 Study 5/18/2015
Agios (AGIO) Announces FDA Fast Track Designation Granted To AG-120 For Treatment Of Patients With Acute Myelogenous Leukemia With An IDH1 Mutation 5/18/2015
Idera Pharmaceuticals, Inc. (IDRA) Provides Development Update On IMO-9200, An Antagonist Of Toll-Like Receptors 5/18/2015
Portola Pharmaceuticals, Inc. Announces Upcoming Data Presentation On Dual Kinase Inhibitor Cerdulatinib At ASCO Annual Meeting 5/18/2015
Significant Progress For Pluristem Therapeutics (PSTI): PLX Cells Were Selected For European Medicines Agency's Adaptive Pathways Pilot Project 5/18/2015
AbGenomics Corporation Announces Initiation Of Phase-Ib/Iia Clinical Trial Of Neihulizumab (AbGn-168H) For The Treatment Of Steroid Refractory Acute GvHD (aGvHD) 5/18/2015
Fraunhofer ITEM: Successful Testing Of New Drug For Allergic Asthma 5/18/2015
Alnylam (ALNY) Files Clinical Trial Application (CTA) for ALN-AAT, An Investigational RNAi Therapeutic For The Treatment Of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease (Alpha-1 Liver Disease) 5/18/2015
Genentech (RHHBY) Lung Cancer Treatments Shrink Tumors, Prolong Life 5/15/2015
TapImmune Inc. (TPIV) Release: Phase I Study In Ovarian & Breast Cancer Published In Abstracts Of 2015 ASCO Annual Meeting 5/15/2015
Genentech (RHHBY)’s Investigational Medicine Alectinib Shrank Tumors In Nearly Half Of People With Specific Type Of Lung Cancer 5/14/2015
SAGE Therapeutics Elated as Brain Seizure Drug Shows 77% Response Rate 5/14/2015
Novogen Limited (NVGN) Release: Anisina Confirmed As Effective Anti-Cancer Agent In Animal Studies 5/14/2015
VBL Therapeutics (VBLX) To Present Positive Phase I/II Data For VB-111 In Recurrent Platinum-Resistant Mullerian Cancer At ASCO Annual Meeting 5/14/2015
Immune Design Corporation (IMDZ) Announces Positive Data From Three Phase I Studies At The 2015 ASCO Annual Meeting 5/14/2015
StemCells (STEM) Announces Positive Top-Line Results Of Its Thoracic Spinal Cord Injury Phase I/II Study 5/14/2015
Astellas Pharma Inc. (ALPMY) Announces New Data In Advanced Prostate And Breast Cancers, Acute Myeloid Leukemia, And Lung And Renal Cancers To Be Presented At 2015 ASCO Annual Meeting 5/14/2015
Strategic Science & Technologies Announces Completion Of Its Phase 1 Clinical Trial For SST-6007, A First-In-Class Topical Sildenafil Cream, To Treat Female Sexual Arousal Disorder 5/14/2015
TopiVert Starts Phase I Clinical Trial In Ulcerative Colitis 5/14/2015
Dicerna (DRNA) Announces Expansion Of Ongoing DCR-MYC Phase 1 Study To Evaluate Safety And Efficacy In Patients With Advanced Pancreatic Neuroendocrine Tumors (PNETs) 5/14/2015
FDA Grants Orphan Drug Designation To GlycoMimetics, Inc. (GLYC)’ GMI-1271 For Treatment Of Acute Myleogenous Leukemia (AML) 5/14/2015
Heron Therapeutics, Inc. (APPA) Announces Positive Outcome From Meeting With FDA For HTX-019 5/14/2015
Biocryst Pharmaceuticals (BCRX) Announces Initiation Of A Phase I Clinical Trial Of BCX7353 For The Treatment Of Hereditary Angioedema 5/13/2015
Oxford University, GlaxoSmithKline (GSK) And Emergent BioSolutions (EBS) Announce Initiation Of A Prime Boost Study Of Ebola Vaccine Candidates 5/13/2015
Bavarian Nordic (BAVA.CO) Announces Presentation Of Preliminary Phase 1 Results For The Ebola Prime-Boost Vaccine Regimen Of MVA-BN Filo And Janssen Pharmaceutical's AdVac Technology 5/13/2015
Public Statement From EuroVacc Foundation And IDT Biologika, Switzerland, Germany, May 13, 2015 5/13/2015
Inovio Pharmaceuticals (INO) Initiates Clinical Trial With DNA Immunotherapies To Prevent And Treat Ebola 5/12/2015
Dana-Farber Cancer Institute And Boston Children's Hospital Opens Phase I Trial Of Immunotherapy For Children With Relapsed Or Treatment-Resistant Leukemia 5/12/2015
Genelux Corporation To Present Posters Supporting Lead Oncolytic Viral Therapy GL-ONC1 At ASCO Annual Meeting 2015 5/12/2015
BEAT BioTherapeutics To Present New Data Supporting The Effectiveness Of BB-R12 In Treating Heart Failure 5/12/2015
ViaCyte, Inc. (Formerly Known as Novocell, Inc.) To Present At Cavendish Global Health Impact Forum 5/11/2015
Heat Biologics Announces Initiation Of Phase Ib Trial Of Viagenpumatucel-L (HS-110) In Non-Small Cell Lung Cancer (NSCLC) 5/11/2015
Jazz Pharmaceuticals (JAZZ) And Concert Pharmaceuticals Provide JZP-386 Program Update 5/8/2015
Mologen AG (MOLGF.PK): Aarhus University Hospital Initiates MGN1703 Study In HIV Patients 5/8/2015
TetraLogic Pharmaceuticals (TLOG)’s New IPO Takes A Hit As Company Halts Hepatitis B Trial 5/7/2015
Retrophin (RTRX) Receives FDA Orphan Drug Designation For RE-024 For The Treatment Of Pantothenate Kinase-Associated Neurodegeneration 5/6/2015
Tyrogenex, Inc. Presents Phase I Study Of X-82 For Wet AMD At The Annual Meeting Of The Association for Research in Vision & Ophthalmology 5/6/2015
MabVax Therapeutics, Inc.' Human Antibody Clinical Development Candidate HuMab 5B1 Successfully Clears Important Early Toxicology Testing 5/5/2015
ZIOPHARM Oncology, Inc. (ZIOP.OB) Announces Initiation Of Phase I Study Of Ad-RTS-IL-12 Gene Therapy In Patients With Brain Cancer 5/5/2015
Kineta Inc. Announces Promising Top-Line Clinical Results For Dalazatide; Target Implicated In Broad Array Of Autoimmune Diseases 5/5/2015
Arrowhead Research Corporation (ARWR) Completes Dosing Healthy Volunteers And Initiates Transition To Patients In Phase 1 Study Of ARC-AAT 5/5/2015
CytRx Corporation (CYTR) Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage And Improved Quality Of Life In Chemotherapy Resistant Cancers 5/4/2015
Aeolus Pharmaceuticals Inc. (AOLS.OB) Announces Complete Results From Successful Study Showing AEOL 10150 Doubles Survival Rate Following Lung Damage Caused By Acute Radiation Exposure 5/4/2015
GliaCure Initiates Phase 1b Dosing In Alzheimer's Patients 5/4/2015
STEM CELLS Translational Medicine Release: Clinical Trial Moves Stem Cell Therapy For ALS Patients One Step Closer To Reality 5/4/2015
Drawbridge Pharmaceuticals Moves Phaxan Forward 5/4/2015
Basilea Pharmaceutica (BSLN.SW) Reports Start Of First-In-Human Phase I Oncology Study With Oral Panraf Kinase Inhibitor 5/4/2015
Sorrento Therapeutics, Inc. Shows Off Positive TRIBECA Registrational Study Results 5/4/2015
Retrophin (RTRX) Announces FDA Review Of IND For RE-024 And Clearance To Proceed With Phase 1 Clinical Study In Healthy Adult Volunteers 5/1/2015
greenovation Biotech GmbH Filed Phase I Clinical Trial Application For Its moss-aGal Compound Intended For Treatment Of Patients Suffering From Fabry Disease 5/1/2015
Lycera Initiates Phase 1 Clinical Trial Of LYC-30937, A First-In-Class Atpase Modulator For Inflammatory Bowel Disease 4/30/2015
Arno Therapeutics Receives European Orphan Drug Designation For AR-12 To Treat Two Infectious Diseases 4/30/2015
The Myelin Repair Foundation And NIH Initiate Clinical Studies Of Guanabenz For Treatment Of Multiple Sclerosis 4/30/2015
ImmunoGen (IMGN) Has Good News, Bad News as Sanofi (SAN.PA) SAAR3419 Deal Falls Apart and Ovarian Cancer Treatment Moves Forward 4/29/2015
Ascendis Pharma A/S Announces Results Of Phase 1 Study Of Transcon Treprostinil 4/29/2015
Arena Pharmaceuticals, Inc. (ARNA) Reports Favorable Results From Phase 1 Single-Ascending Dose Clinical Trial Of APD371 4/29/2015
Benitec Biopharma Doses Fifth Patient And Initiates Additional Trial Site For Hepatitis C Trial 4/29/2015
Celsion Corporation (CLSN) Expands Clinical Development Plan For GEN-1 IL-12 Immunotherapy Program In Ovarian Cancer 4/29/2015
ContraFect (CFRXU) Announces Commencement Of Phase 1 Clinical Trial Of Cf-301 For Staph Bloodstream Infections, Including MRSA 4/29/2015
Constellation Pharmaceuticals Initiates Clinical Development Of CPI-1205, A Novel Inhibitor Of EZH2, In Patients With Lymphoma 4/28/2015
PTC Therapeutics (PTCT)' Cancer Stem Cell Program Targeting BMI1 Enters Phase 1 4/28/2015
aTyr Pharma Receives U.S. FDA Orphan Designation For Resolaris 4/27/2015
Aratana Therapeutics (PETX) Comments On ADXS31-164 (AT-014) Study Data Presented During Poster Session At The AACR Annual Meeting 2015 4/27/2015
ZIOPHARM, Inc. Announces Initiation of Phase 1b/2 Study of Ad-RTS-hIL-12 Gene Therapy in Patients With Locally Advanced or Metastatic Breast Cancer 4/27/2015
EXCLUSIVE: Jounce CEO Says Funding Aims for Trials Next Year, Will Hire 10 4/27/2015
GW Pharmaceuticals (GWPH) Receives Orphan Drug Designation From FDA For Cannabidiol For The Treatment Of Neonatal Hypoxic-Ischemic Encephalopathy 4/24/2015
Gilead (GILD)’s Hepatitis C Combo Shows Cure Rate of 93% At Six Weeks, Fails at Four 4/23/2015
Merck & Co. (MRK)'s Keytruda Effective Against Three Cancers 4/23/2015
Tisch MS Research Center Of New York Reports Early Improvement In Stem Cell Trial 4/23/2015
INSYS Therapeutics Commences Dosing In Phase 1/2 Safety And Pharmacokinetic Study Of Cannabidiol Oral Solution In Pediatric Epilepsy Patients 4/23/2015
Nordic Nanovector: Results Of Phase 1 Study Of Betalutin In Patients With Non-Hodgkin Lymphoma To Be Presented At The International Conference On Malignant Lymphoma 4/23/2015
Strategia Therapeutics Initiates A Phase 1/2a Clinical Trial Of The Anti-Cancer Agent E6201 In Patients With Advanced Hematologic Malignancies 4/22/2015
SolaranRx’s SRX-1177 Receives FDA Orphan Drug Designation As Malignant Melanoma Treatment 4/22/2015
Acorda Therapeutics (ACOR) Presents Data On First Clinical Study Of Remyelinating Antibody For Multiple Sclerosis At American Academy of Neurology Annual Meeting 4/22/2015
Verastem, Inc. (VSTM) Presents Encouraging Scientific Data On The Preferential Targeting Of Cancer Stem Cells At The 2015 AACR Annual Meeting 4/22/2015
Heat Biologics. To Present At The 2015 AACR Annual Meeting 4/22/2015
Triphase Accelerator Initiates Phase I Study Of Marizomib And Bevacizumab In Patients With Glioblastoma 4/22/2015
CAR-T Cell Companies Juno Therapeutics (JUNO), Kite Pharma (KITE), and ZIOPHARM, Inc. Get Stock Jitters on Disappointing Novartis AG (NVS) Trial News 4/22/2015
Pfizer (PFE) Snags FDA Breakthrough Therapy Tag for Xalkori 4/21/2015
Inovio Pharmaceuticals (INO) And Roche (RHHBY) Initiate Clinical Trial For Inovio's DNA Immunotherapy To Treat Chronic Hepatitis B Infection 4/21/2015
Arno Therapeutics To Present Promising Data From Phase I Trial Of Onapristone At AACR Annual Meeting 2015 4/21/2015
Cortice Biosciences Announces Updated Results From A Phase 1/2 Clinical Trial Evaluating TPI 287 For Treatment Of Recurrent Glioblastoma 4/21/2015
New Data Show Rexahn Pharmaceuticals, Inc. (RNN)'s Supinoxin Decreases The Migration Of Human Triple Negative Breast Cancer Cells In A Metastatic Cancer Model 4/21/2015
Pfizer (PFE) Receives FDA Breakthrough Therapy Designation For XALKORI (crizotinib) For The Treatment Of Patients With ROS1-Positive Non-Small Cell Lung Cancer 4/21/2015
Merrimack (MACK) Announces Final Clinical Results For MM-302 Phase 1 Study Demonstrating Robust Activity In Heavily Pre-Treated Patients With HER2-Positive Metastatic Breast Cancer 4/21/2015
Juno Therapeutics (JUNO)' CAR T Cell Product Candidate JCAR017 Continues To Demonstrate Encouraging Outcomes In Pediatric Patients With Relapsed/Refractory CD19 Positive Acute Lymphoblastic Leukemia 4/21/2015
ArQule, Inc. (ARQL) Announces Data Presentations With ARQ 087, Inhibitor Of FGFR, At AACR 4/21/2015
Merrimack (MACK) Release: First-in-Human Phase 1 Trial Of MM-141 Demonstrates Activity In Biomarker Positive Patients 4/21/2015
Nimbus Therapeutics Announces Initiation Of Clinical Studies For ACC Inhibitor 4/21/2015
Kineta Inc., University of Groningen Present New, Positive Data For Dalazatide In ANCA Vasculitis, An Orphan Disease 4/21/2015
Loxo Oncology (LOXO)'s LOXO-101 Demonstrates Encouraging Initial Results From Ongoing Phase Ia Dose Escalation Study 4/21/2015
MediciNova, Inc. Announces Positive Interim Safety Data From Clinical Trial Of MN-166 (Ibudilast) In ALS 4/21/2015
Early Findings With KEYTRUDA (Pembrolizumab), Merck & Co. (MRK)’s Anti-PD-1 Therapy, In Patients With Advanced Pleural Mesothelioma Presented At American Association for Cancer Research Annual Meeting 4/20/2015
ChemoCentryx, Inc. (CCXI) Initiates Clinical Trial Of CCX872, Its Next-Generation, Orally Administered CCR2 Inhibitor, In Pancreatic Cancer 4/20/2015
Merck & Co. (MRK) Release: Treatment Of Advanced Non-Small Cell Lung Cancer (NSCLC) With Pembrolizumab Presented At AACR Annual Meeting And Published In The New England Journal of Medicine 4/20/2015
OncoCyte Corporation Announces Initial Data From Ongoing Clinical Study Of Collagen Type X As A Marker And Potential Diagnostic For Breast Cancer And Other Types Of Human Cancers 4/20/2015
Epizyme (EPZM) To Present Updated Data From Ongoing Phase 1 Dose Escalation Trial Of EZH2 Inhibitor EPZ-6438 At International Conference On Malignant Lymphoma 4/20/2015
PTC Therapeutics (PTCT) Phase 1 Data From Spinal Muscular Atrophy Program To Be Presented At The 2015 American Academy of Neurology Annual Meeting 4/20/2015
cCam Biotherapeutics Announces Initiation Of Phase 1 Trial Of CM-24, A Novel Immune Checkpoint Inhibitor For Cancer Immunotherapy 4/20/2015
Cardio3 Biosciences Announces Infusion Of First Patient In NKG2D Phase I Trial With No Short Term Adverse Events 4/20/2015
AstraZeneca PLC (AZN)'s Experimental Lung Cancer Drug Delays Disease By More Than a Year 4/20/2015
Bionomics Limited (BNO.AX) Showcases Oncology Drug Development Programs At 2015 American Association for Cancer Research Annual Meeting 4/17/2015
Cellectar Biosciences  (NVLT) Initiates Proof-Of-Concept Trial Of I-131-CLR1404 In Multiple Myeloma 4/16/2015
Avelas Biosciences Initiates Phase 1b Trial Of AVB-620 In Breast Cancer Patients 4/16/2015
EMD Serono Highlights Scientific Commitment To MS With Data Presented At The American Academy of Neurology Annual Meeting 4/16/2015
OncoMed Pharmaceuticals, Inc. (OMED) Presents Demcizumab Data From Phase 1b Clinical Trial In Non-Small Cell Lung Cancer Patients At The European Lung Cancer Conference 4/16/2015
Targacept (TRGT) Announces Negative Top-Line Results From Exploratory Study Of TC-6499 In Diabetic Gastroparesis 4/16/2015
Protalex, Inc. (PRTX) Announces Findings From Final Cohort Of U.S. Phase Ib Trial Of PRTX-100 In Active Rheumatoid Arthritis Patients 4/16/2015
Isarna Therapeutics Initiates First-In-Human Phase I Trial For ISTH0036 To Treat Advanced Glaucoma 4/16/2015
PsiOxus Therapeutics Limited Expands Clinical Studies For Immuno-Oncolytic Treatment Following Positive Response To Intravenous Delivery 4/16/2015
DelMar Pharmaceuticals Adds Fourth Clinical Trial Site In Phase I/II Multicenter Study Of VAL-083 For Recurrent Malignant Glioma 4/16/2015
SELLAS Life Sciences Group And Trojantec Ltd. Sign Exclusive License Agreement For Global Rights On Development And Commercialization Of Innovative TR-1 Anti-Cancer Antennapedia Technology 4/15/2015
Replicel Life Sciences Receives Approval To Conduct Clinical Trial For Patients With Chronic Achilles Tendinosis 4/15/2015
Hydra Biosciences, Inc. Receives Approval From Health Canada To Begin Phase 1 Trial For HX-100 4/14/2015
Prolong Pharmaceuticals Presents Data On Unique "Un-Sickling" In Vitro Activity Observed In Sickle Cell Investigational Drug SANGUINATE 4/14/2015
InnFocus FDA Phase One Enrollment Reaches 75 Patient Filing Milestone 4/13/2015
Upsher-Smith Laboratories To Present Data Evaluating The Long-Term Safety And Efficacy Of Qudexy XR (Topiramate) Extended-Release Capsules And Alternative Administration Techniques 4/13/2015
Cytori Therapeutics, Inc. (CYTX) Provides Twelve Month Data Update On Scleradec-I Trial 4/13/2015
Suven Life Sciences Ltd Initiated Multiple Ascending Dose (MAD) Studies In Phase 1 Clinical Trial For Their Investigational Compound SUVN-G3031 4/13/2015
Cell MedX Corp. (CMXC) Announces Additional Results Of Preliminary Analysis Of Metabolomic Assays In Phase 1 Pilot Clinical Trial 4/13/2015
Cardio3 BioSciences Enrolls First Patient in Phase I Trial For NKG2D CAR T-Cell 4/13/2015
FDA Modifies Partial Clinical Hold On Tekmira (TKMR)'s TKM-Ebola IND To Allow Multiple Dosing Of Healthy Volunteers 4/10/2015
Eisai Company (ESALY.PK) And Arena Pharmaceuticals, Inc. (ARNA) Complete Registrational Trials Of An Extended Release Formulation Of Lorcaserin 4/10/2015
Sihuan Pharmaceutical Starts US Trial Of Novel Cancer Drug 4/10/2015
MedImmune (AZN) Release: MEDI8897 Receives Fast Track Designation By The FDA For The Prevention Of Respiratory Disease Caused By RSV In Infants 4/9/2015
VBI Vaccines Announces New Data Supporting The Manufacture Of Its Prophylactic CMV Vaccine Candidate 4/9/2015
Advaxis, Inc. And Merck & Co. (MRK) Announce Initiation Of Enrollment In The Phase I/II Study Of ADXS-PSA In Combination With Anti-PD-1 Therapy, KEYTRUDA (Pembrolizumab), For The Treatment Of Advanced Prostate Cancer 4/8/2015
Prolong Pharmaceuticals' Flagship Product SANGUINATE Granted Orphan Drug Designation By The FDA 4/8/2015
Benitec, Inc. (BLT.AX) Provides Update On TT-034 Trial 4/7/2015
Targacept (TRGT) Abandons Nictoine Focus for Alzheimer's 4/6/2015
Celldex (CLDX) Announces Initiation Of Phase 1/2 Study Of Varlilumab In Combination With Ipilimumab And CDX-1401 In Metastatic Melanoma 4/6/2015
Curis, Inc. (CRIS) Announces Orphan Drug Designation For CUDC-907 In Diffuse Large B-Cell Lymphoma 4/6/2015
Immunomedics, Inc. (IMMU) To Provide Update On Sacituzumab Govitecan For The Therapy Of Solid Cancers 4/6/2015
Public Health Agency of Canada Release: Clinical Trials Prove Canada's VSV-EBOV Ebola Vaccine Safe And Effective 4/2/2015
Luye Pharma Reports Successful Phase I Trials Of Novel Anti-depressant 4/2/2015
Immune Design Corporation (IMDZ) Announces Positive Topline Data From Three Phase 1 Clinical Trials Of Immuno-Oncology Agents 4/1/2015
ESSA Pharma Announces Filing Of Investigational New Drug Application For EPI-506 4/1/2015
Sigma-Tau Pharmaceuticals Receives Orphan Drug Designation For STP-206 For Prevention Of Necrotizing Enterocolitis 4/1/2015
Idera Pharmaceuticals, Inc. (IDRA) Announces FDA Orphan Drug Designation For IMO-8400 For The Treatment Of Diffuse Large B-Cell Lymphoma 4/1/2015
Pharmacyclics (PCYC) Release: Solid Tumor Study Investigating Ibrutinib (IMBRUVICA) In Combination With Anti-PD-L1 Antibody (MEDI4736) Commences In Patients With Relapsed/Refractory Non-Small Cell Lung, Breast And Pancreatic Cancers 4/1/2015
Portage Biotech's Biohaven Announces Agreement With inVentiv Health (VTIV) 4/1/2015
Oramed Pharmaceuticals Inc. (ORMP) Enrolls First Patient In Its Glucose Clamp Study For Oral Insulin 4/1/2015
Dyax Corp. (DYAX) Announces Positive Results From Phase Ib Clinical Trial Of DX-2930 4/1/2015
Vaccinex, Inc. Provides An Update On Its VX15/2503 Phase 1 Clinical Trial In Multiple Sclerosis Patients 3/31/2015
PledPharma Presents Top-Line Results From Its PhaseIIb Study - Pledox(R) Reduces Nerve Damage In Conjunction With Chemotherapy By 43 Percent 3/30/2015
Lion Biotechnologies, Inc. Announces Positive Data From A TIL-Ipilimumab Combination Study In Melanoma 3/30/2015
Matinas BioPharma Completes Enrollment In First Human Trial Of MAT9001 3/30/2015
Novavax, Inc. (NVAX) Presents New Data From Non-Human Primate Ebola Challenge At The 7th International Symposium On Filoviruses 3/30/2015
DURECT Corporation (DRRX) Announces Initiation Of DUR-928 Multi-Dose Phase 1 Study 3/30/2015
PRA Health Sciences Expands Global Phase I Patient Strategy 3/30/2015
IntelliPharmaCeutics Reports Positive Topline Data Results From A Series Of Phase I Clinical Trials Of Its Abuse-Deterrent Rexista(TM) Oxycodone XR Tablets, And Files An IND For Rexista(TM) Oxycodone XR 3/30/2015
Calithera Biosciences, Inc. (CALA) Reports Fourth Quarter And Full Year 2014 Financial Results And Recent Highlights 3/27/2015
New Research Throws Cold Water on Biogen (BIIB)'s Recent Breakthrough 3/26/2015
Aridis Pharmaceuticals Commences Phase 1 Clinical Study Of Aerucin Monoclonal Antibody For Acute Pneumonia 3/26/2015
Transition Therapeutics Inc. (TTH.TO) Announces Results From Phase 1 AME & Renal Clearance Clinical Studies Of Neuropsychiatric Drug Candidate ELND005 3/26/2015
Essentialis Presents Results From The First Phase Of Clinical Study PC025 Evaluating DCCR In The Treatment Of Prader-Willi Syndrome At ACMG Annual Clinical Genetic Meeting 3/26/2015
Immune Design Corporation (IMDZ) Announces Treatment Of Patients With CMB305 Investigational Immuno-Oncology Agent 3/26/2015
Tianjin CanSino Biotechnology Release: China Ebola Vaccine Passes Phase I Test 3/26/2015
Zogenix (ZGNX) Announces First Patient Dosed In Relday Multi-Dose Clinical Study 3/26/2015
Vical Incorporated (VICL) Expands Infectious Disease Portfolio With Novel Antifungal From Astellas Pharma Inc. (ALPMY) 3/26/2015
MorphoSys AG And Celgene (CELG) Mutually Agree To End MOR202 Collaboration 3/26/2015
Aduro Biotech Receives Orphan Drug Designation For CRS-207 In Mesothelioma 3/26/2015
Cardio3 BioSciences Reports 2014 Financial And Operating Results 3/26/2015
Regulus Therapeutics, Inc. (RGLS) Receives Orphan Medicinal Product Designation From The European Commission (EC) For RG-012, A Microrna Therapeutic In Development For The Treatment Of Alport Syndrome 3/25/2015
Cellular Biomedicine Group (CBMG) Announces Phase I Results From CAR-T Immuno-Oncology Clinical Development Programs 3/25/2015
Therapure Innovations Receives FDA Approval To Proceed With A Phase 1 Clinical Trial Of The Targeted Liver Cancer Therapeutic TBI 302 3/25/2015
BioLineRx Ltd. Reports Successful Top-Line Safety And Efficacy Results For Novel Stem Cell Mobilization Treatment 3/25/2015
Tenth Cohort Completed In Cellceutix (CTIX) Clinical Trial Of Anti-Cancer Drug Kevetrin, No Adverse Events Reported 3/25/2015
Biogen (BIIB) Alzheimer's Drug Aducanumab Exceeds Expectations 3/25/2015
Relmada Therapeutics Receives Health Canada Clearance To Commence First Clinical Study For Novel Oral Formulations Of Buprenorphine 3/24/2015
GenVec Inc. (GNVC) Reports Fourth Quarter And 2014 Year-End Financial Results 3/24/2015
Biogen (BIIB) Drops Idec From Corporate Name, Expands Ambitions in Alzheimer's, ALS 3/24/2015
Prothena (PRTA) Soars on Positive Phase I Results Of Parkinson's Drug PRX002 3/24/2015
Eli Lilly (LLY),Novartis AG (NVS)-Backed Startup, Aeglea, Nabs $44 Million 3/23/2015
Biogen (BIIB) Slides For Alzheimer's Drug Wow Analysts, Set Up Fight for Eli Lilly (LLY) 3/23/2015
Isis Pharmaceuticals, Inc. (ISIS) Reports Positive Phase 1 Data on Isis-ANGPTL3Rx 3/23/2015
GenVec Inc. (GNVC) And TheraBiologics Form Collaboration To Develop Neural Stem Cell Mediated Cancer Therapies 3/23/2015
AB Science (AB.PA): Masitinib Receives Orphan Drug Designation For Amyotrophic Lateral Sclerosis From FDA 3/23/2015
Kamada Ltd. (KMDA) Awarded European Orphan Drug Designation For Its Alpha-1 Antitrypsin To Treat Graft-Versus-Host Disease 3/23/2015
Another Day, Another $456 Million Cancer Pact for Eli Lilly (LLY) 3/23/2015
Biogen Idec (BIIB) Presents Positive Interim Results From Phase 1B Study Of Investigational Alzheimer’s Disease Treatment Aducanumab (BIIB037) At 2015 AD/PD Conference 3/20/2015
Alzheon Announces Phase 1 Results Of ALZ-801, A First-in-Class Inhibitor Of Amyloid Formation And Neurotoxicity For Alzheimer’s Disease 3/20/2015
Eli Lilly (LLY), Hanmi Pharma Forge $690 Million Autoimmune Pact 3/19/2015
Synthetic Biologics, Inc. (SYN) Announces Positive Pharmacokinetics Data From Phase 1a And 1b Trials Of SYN-004 To Protect The Microbiome And Prevent C. difficile Infection 3/19/2015



//-->